Cancer CellPub Date : 2026-09-14DOI: 10.1016/j.ccell.2026.07.014
Carmen Mota Reyes,Mara R. Goetz,Hana Algül,Alper Dogruoez,Chiara Falcomatà,Matthias M. Gaida,Kıvanç Görgülü,Yetiş Gültekin,Ibrahim Halil Gürcinar,Marie C. Hasselluhn,Rouzanna Istvanffy,Raghu Kalluri,Valerie S. Kalluri,Ashley Kiemen,Pilhan Kim,Sang-Won Lee,Marina Lesina,Peter Yu,Anirban Maitra,Clara M. Müller,Sebastian Müller,Dowoon Nam,Kenneth P. Olive,Marina Pasca Di Magliano,Roland Rad,Dieter Saur,Matthew G. Vander Heiden,Mathias Vormehr,Laura D. Wood,Eyüp Yöndem,David Zschäpitz,Didem Karakas,Helmut Friess,Güralp O. Ceyhan,European Pancreatic Club (EPC) Pancreatic Cancer Think Tank Group,Ihsan Ekin Demir
{"title":"Pancreatic ductal adenocarcinoma: The Vision of Heracles","authors":"Carmen Mota Reyes,Mara R. Goetz,Hana Algül,Alper Dogruoez,Chiara Falcomatà,Matthias M. Gaida,Kıvanç Görgülü,Yetiş Gültekin,Ibrahim Halil Gürcinar,Marie C. Hasselluhn,Rouzanna Istvanffy,Raghu Kalluri,Valerie S. Kalluri,Ashley Kiemen,Pilhan Kim,Sang-Won Lee,Marina Lesina,Peter Yu,Anirban Maitra,Clara M. Müller,Sebastian Müller,Dowoon Nam,Kenneth P. Olive,Marina Pasca Di Magliano,Roland Rad,Dieter Saur,Matthew G. Vander Heiden,Mathias Vormehr,Laura D. Wood,Eyüp Yöndem,David Zschäpitz,Didem Karakas,Helmut Friess,Güralp O. Ceyhan,European Pancreatic Club (EPC) Pancreatic Cancer Think Tank Group,Ihsan Ekin Demir","doi":"10.1016/j.ccell.2026.07.014","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.07.014","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies, as tumors evolve faster than therapies. Resistance is ecological, not merely KRAS driven, involving overlooked players like high-grade pancreatic intraepithelial neoplasias (PanINs), peripancreatic fat, stromal mechanics, myeloid-neural circuits, metabolic rewiring, and systemic host responses. We propose precision interception targeting PanIN/intraductal papillary mucinous neoplasm (IPMN) biology, spatial-functional-proteogenomic classification beyond transcriptomics, the Heracles Protocol (measure, prime, strike, and adapt), and integrated technologies from AI pathology to exosomal delivery and CRISPR-based synergy mapping, together making PDAC more tractable.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"37 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148957857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-09-14DOI: 10.1016/j.ccell.2026.08.005
Rouven Hoefflin,Alissa C. Greenwald,Noam Galili Darnell,Christopher W. Mount,Yali Tiomkin,L. Nicolas Gonzalez Castro,Zebin Wen,Dor Simkin,Angelica B. Patterson,Inna Goliand,Ofra Golani,Liat Fellus-Alyagor,Marina Cohen,Kevin Joseph,Jürgen Beck,Vidhya M. Ravi,Merav Kedmi,Hadas Keren-Shaul,Michael Weller,Yoseph Addadi,Marian C. Neidert,Mario L. Suvà,Itay Tirosh
{"title":"Spatial analysis reveals the evolving organization of IDH-mutant glioma","authors":"Rouven Hoefflin,Alissa C. Greenwald,Noam Galili Darnell,Christopher W. Mount,Yali Tiomkin,L. Nicolas Gonzalez Castro,Zebin Wen,Dor Simkin,Angelica B. Patterson,Inna Goliand,Ofra Golani,Liat Fellus-Alyagor,Marina Cohen,Kevin Joseph,Jürgen Beck,Vidhya M. Ravi,Merav Kedmi,Hadas Keren-Shaul,Michael Weller,Yoseph Addadi,Marian C. Neidert,Mario L. Suvà,Itay Tirosh","doi":"10.1016/j.ccell.2026.08.005","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.08.005","url":null,"abstract":"Adult diffuse gliomas are composed of malignant cell states interwoven with the non-malignant brain microenvironment. Here, we combine spatial transcriptomics and spatial proteomics of isocitrate dehydrogenase (IDH)-mutant gliomas to define organizational principles across histological grades. In low-grade tumors, spatial organization is shaped by underlying brain anatomy. We identify a functional white-gray matter junction that restricts cortical invasion and is associated with marked changes in tumor composition and cellular phenotypes. This junction is preferentially traversed by oligodendrocyte progenitor (OPC)-like malignant cells, suggesting a role in tumor expansion. In contrast, tumors with intermediate histological features are largely disorganized, with few recurring interactions between cancer cell states and microenvironmental cell types. In high-grade tumors, hypoxia-associated structure emerges, resembling IDH-wild-type glioblastoma. Together, these findings reveal two independent axes of spatial organization—from anatomy-driven structure in low-grade tumors to hypoxia-driven organization in high-grade tumors—and establish a framework linking tumor grade to recurrent spatial interactions.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"37 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148957870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-09-14Epub Date: 2026-09-01DOI: 10.1016/j.ccell.2026.06.016
Wee Loong Chin, Willem Joost Lesterhuis
{"title":"TIME in motion: How response takes shape.","authors":"Wee Loong Chin, Willem Joost Lesterhuis","doi":"10.1016/j.ccell.2026.06.016","DOIUrl":"10.1016/j.ccell.2026.06.016","url":null,"abstract":"<p><p>Biomarkers for immune checkpoint inhibitors have largely treated the tumor immune microenvironment as a fixed property. In this issue of Cancer Cell, Lin et al. assemble a longitudinal pan-cancer single-cell atlas and show that the direction of immune-state remodeling during therapy is more informative than baseline composition.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"1735-1736"},"PeriodicalIF":56.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-09-14Epub Date: 2026-09-01DOI: 10.1016/j.ccell.2026.08.007
Zhongyang Lin, Mitalee Chandra, Nalini Srinivas, Selma Ugurel, Jürgen C Becker, Dvir Aran
{"title":"Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy.","authors":"Zhongyang Lin, Mitalee Chandra, Nalini Srinivas, Selma Ugurel, Jürgen C Becker, Dvir Aran","doi":"10.1016/j.ccell.2026.08.007","DOIUrl":"10.1016/j.ccell.2026.08.007","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet the basis of variable patient responses remains unclear. We assemble a longitudinal single-cell RNA sequencing atlas of 441 samples from 241 patients across ten cancer entities to map treatment-associated remodeling of the tumor immune microenvironment (TIME). With a hierarchical reference-guided deep-phenotyping framework, we define 77 immune and stromal subtypes and resolve four conserved TIME subtypes. Approximately 40% of tumors shift between states during therapy, and the transition is more predictive of outcome than the baseline state. Favorable transitions toward inflamed or B cell-enriched subtype track with improved response and survival, while persistence in or shifts toward myeloid dominance indicate resistance. We derive a 59-gene signature that predicted response and survival for 1,383 baseline tumors across 19 independent cohorts. These findings establish immunotype transitions as a central determinant of ICI efficacy, offering new avenues for response prediction and rational immunotherapy design.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"1847-1861.e6"},"PeriodicalIF":56.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-09-14Epub Date: 2026-09-01DOI: 10.1016/j.ccell.2026.07.013
Mathijs P Verhagen, Louis Vermeulen
{"title":"Tumor evolution shapes metastatic competence in colorectal cancer.","authors":"Mathijs P Verhagen, Louis Vermeulen","doi":"10.1016/j.ccell.2026.07.013","DOIUrl":"10.1016/j.ccell.2026.07.013","url":null,"abstract":"<p><p>In this issue of Cancer Cell, Manca et al. investigate the genomic evolution and metastatic tropism of over 7,000 colorectal cancers. Integrating primary tumor location, genomic alterations, and clinical variables, they reveal how distinct patterns of tumor evolution shape metastatic competence and impact organ tropism, offering a framework to refine surveillance.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"1737-1739"},"PeriodicalIF":56.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-09-14Epub Date: 2026-07-27DOI: 10.1016/j.ccell.2026.07.001
R Ryan Meyerhoff, Alan Chen, Jenny O'Brien, Carmen M Anadon, Luis Uriel Lopez Bailon, Dayan Carrion-Estrada, Koravit Poysungnoen, Jared Lindenberger, Gabor Kemeny, Liliana Lyniv, Vaibjav Jain, Ricardo Chaurio, Noah Plappert, Tyler Evangelous, Chan Soo Park, Alok Sinha, Eziafa Oduah, Carolyn Glass, Kent Weinhold, Simon Gregory, John W Hickey, Priyamvada Acharya, Neal Ready, Jose R Conejo-Garcia, Wilton B Williams, Scott J Antonia
{"title":"Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.","authors":"R Ryan Meyerhoff, Alan Chen, Jenny O'Brien, Carmen M Anadon, Luis Uriel Lopez Bailon, Dayan Carrion-Estrada, Koravit Poysungnoen, Jared Lindenberger, Gabor Kemeny, Liliana Lyniv, Vaibjav Jain, Ricardo Chaurio, Noah Plappert, Tyler Evangelous, Chan Soo Park, Alok Sinha, Eziafa Oduah, Carolyn Glass, Kent Weinhold, Simon Gregory, John W Hickey, Priyamvada Acharya, Neal Ready, Jose R Conejo-Garcia, Wilton B Williams, Scott J Antonia","doi":"10.1016/j.ccell.2026.07.001","DOIUrl":"10.1016/j.ccell.2026.07.001","url":null,"abstract":"<p><p>The role of tumor-infiltrating B cells (TIL-Bs) in shaping anti-tumor responses in the context of immune checkpoint blockade remains incompletely understood. Here, we interrogate the humoral response in resected lung tumors from patients with non-small cell lung cancer (NSCLC) treated with neoadjuvant PD-1 blockade. We find that tumors orchestrate tertiary lymphoid structures with CD138<sup>+</sup> plasma cells, from which we clone recombinant monoclonal antibodies (mAbs) using B cell receptors (BCRs) exhibiting somatic hypermutation and class switching. Several mAbs bind cell-surface citrullinated proteins, characteristic of cancer cells. Chimeric antigen receptor (CAR) T redirected with the soluble chain fragment variable (scFv) of our lead candidate antibody (PC-1) specifically target tumor cells and tumor-promoting myeloid cells in vivo without off-target activity. Moreover, ablation of the citrullination enzyme PADI2 in tumor-bearing mice eliminates reactivity to PC-1 and cytotoxic killing by the CAR. Our results implicate a therapeutic potential for tumor-infiltrating plasma cells that may be harnessed for cancer treatment.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"1815-1831.e11"},"PeriodicalIF":56.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-09-14Epub Date: 2026-08-10DOI: 10.1016/j.ccell.2026.07.011
Niklas Kehl, Tim R Wagner, Simon Steiger, Tamara Boschert, Michael Kilian, Antonia Schach, Julius J Michel, Kane Foster, Gabrielle M Hernandez, Claudia Ctortecka, Anna D Metzler, Alanna Kirschner, Arne Van der Vreken, Dominik Humer, René Onken, Sven Cuntz, Julian Zoller, Cornelius Funk, Selina Neunhäuser, Maximilian Mönnig, Bruno Schönfelder, Simon Renders, Claudia Maldonado Torres, Lilli S Sester, Jan H Frenking, Franziska Werner, Wolfram Osen, Katharina Lindner, Ezgi Sen, Sabrina Schumacher, Daria Galas-Filipowicz, Evie Fitzsimons, Edward W Green, Patrick Schmidt, John M Lindner, Sebastian Uhrig, Lukas Bunse, Benny Chain, Hartmut Goldschmidt, Niels Weinhold, Stefan Fröhling, Tim Sauer, Simon Raffel, Jennifer G Abelin, Steven A Carr, Kwee Yong, Andreas Trumpp, Carsten Müller-Tidow, Karsten Rippe, Marc S Raab, Michael Platten, Stefan B Eichmüller, Mirco J Friedrich
{"title":"Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment.","authors":"Niklas Kehl, Tim R Wagner, Simon Steiger, Tamara Boschert, Michael Kilian, Antonia Schach, Julius J Michel, Kane Foster, Gabrielle M Hernandez, Claudia Ctortecka, Anna D Metzler, Alanna Kirschner, Arne Van der Vreken, Dominik Humer, René Onken, Sven Cuntz, Julian Zoller, Cornelius Funk, Selina Neunhäuser, Maximilian Mönnig, Bruno Schönfelder, Simon Renders, Claudia Maldonado Torres, Lilli S Sester, Jan H Frenking, Franziska Werner, Wolfram Osen, Katharina Lindner, Ezgi Sen, Sabrina Schumacher, Daria Galas-Filipowicz, Evie Fitzsimons, Edward W Green, Patrick Schmidt, John M Lindner, Sebastian Uhrig, Lukas Bunse, Benny Chain, Hartmut Goldschmidt, Niels Weinhold, Stefan Fröhling, Tim Sauer, Simon Raffel, Jennifer G Abelin, Steven A Carr, Kwee Yong, Andreas Trumpp, Carsten Müller-Tidow, Karsten Rippe, Marc S Raab, Michael Platten, Stefan B Eichmüller, Mirco J Friedrich","doi":"10.1016/j.ccell.2026.07.011","DOIUrl":"10.1016/j.ccell.2026.07.011","url":null,"abstract":"<p><p>T cell-mediated immune surveillance is critical for cancer control, yet its role in bone marrow malignancies remains poorly understood. Here, we integrate TCR profiling, HLA immunopeptidomics, and functional screening to characterize tumor-reactive T cells in the bone marrow of patients with multiple myeloma (MM) and acute myeloid leukemia (AML). These cells are transcriptionally defined by a conserved effector program distinct from the exhausted phenotype of tumor-reactive T cells in solid cancers. Immunopeptidomic profiling reveals a partially shared antigen landscape enriched for noncanonical peptides driving convergent TCR responses. We develop TFiT (tumor-reactive features in T cells), a transcriptional classifier that identifies these cells and stratifies immunotherapy, but not chemotherapy, response across independent MM and AML cohorts, supporting its specificity for T cell-mediated tumor control. These findings reveal a latent but activatable anti-tumor T cell compartment in bone marrow malignancies and provide a framework for engaging endogenous immunity in MM and AML.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"1779-1798.e14"},"PeriodicalIF":56.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-09-14DOI: 10.1016/j.ccell.2026.08.002
Daniel J. Silver,Chang Xu,Justin D. Lathia
{"title":"Scherer’s map, remapped","authors":"Daniel J. Silver,Chang Xu,Justin D. Lathia","doi":"10.1016/j.ccell.2026.08.002","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.08.002","url":null,"abstract":"Scherer’s century-old classification of expansive and infiltrative glioma growth remains foundational to neuro-oncology. In this issue of Cancer Cell, Hoefflin et al. use spatial RNA and protein profiling of IDH-mutant gliomas to reveal hypoxia and necrosis as organizing centers of expansive growth and white-matter tracts as guides and constraints on invasion.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"150 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148957860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CellPub Date : 2026-09-14Epub Date: 2026-09-01DOI: 10.1016/j.ccell.2026.08.004
Paolo Manca, Henry Walch, Jierui Xu, Natalie Small, Ayush Kris, Evan Seffar, Allison Richards, Tiffany Xue, Adam Price, Mark T A Donoghue, Christopher Fong, Michele Waters, Justin Jee, Sachin Kumar Deshmukh, George W Sledge, Midhun Malla, Andrea Cercek, Leonard Saltz, Neil H Segal, Zsofia K Stadler, Maliha Nusrat, Michael B Foote, Avni Desai, Sree Chalasani, Devika Rao, Louise Connell, Richard K G Do, Karuna Ganesh, Martin R Weiser, Michael F Berger, David B Solit, Jinru Shia, Efsevia Vakiani, Julio Garcia-Aguilar, Nikolaus Schultz, Francisco Sanchez-Vega, Walid K Chatila, Rona Yaeger
{"title":"Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer.","authors":"Paolo Manca, Henry Walch, Jierui Xu, Natalie Small, Ayush Kris, Evan Seffar, Allison Richards, Tiffany Xue, Adam Price, Mark T A Donoghue, Christopher Fong, Michele Waters, Justin Jee, Sachin Kumar Deshmukh, George W Sledge, Midhun Malla, Andrea Cercek, Leonard Saltz, Neil H Segal, Zsofia K Stadler, Maliha Nusrat, Michael B Foote, Avni Desai, Sree Chalasani, Devika Rao, Louise Connell, Richard K G Do, Karuna Ganesh, Martin R Weiser, Michael F Berger, David B Solit, Jinru Shia, Efsevia Vakiani, Julio Garcia-Aguilar, Nikolaus Schultz, Francisco Sanchez-Vega, Walid K Chatila, Rona Yaeger","doi":"10.1016/j.ccell.2026.08.004","DOIUrl":"10.1016/j.ccell.2026.08.004","url":null,"abstract":"<p><p>We performed an integrated clinical and genomic analysis of over 7,000 consecutively sequenced colorectal cancer (CRC) samples to comprehensively characterize genetic drivers and metastatic tropisms of CRC. We find that genomic evolutionary changes, such as clonal mutations and oncogenic mutant allelic imbalance, selectively enhance the impact of recurrent oncogenic alterations. We identify the relative timing of organ-specific metastasis, showing sequential metastatic progression in microsatellite stable CRC with brain and adrenal metastases as late events; metastatic sites that cluster together, such as lung, bone, and brain metastases; and genomic events that enhance or decrease risk for each metastatic site, with WNT pathway activation as overall protective while RAS pathway activation increased risk for spread to all metastatic sites. Our data suggest that despite the heterogeneity in CRC, genomic evolution increases the impact of recurrent alterations, and integrating information about tumor primary location and genomics can be used to predict organ-specific metastasis risk.</p>","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":" ","pages":"1746-1760.e4"},"PeriodicalIF":56.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Molecular residual disease: Charting a new path for treating resectable solid tumors","authors":"Shin Kobayashi,Tadayoshi Hashimoto,Hideaki Bando,Yoshiaki Nakamura,Aparna Parikh,Jeanne Tie,Qian Shi,Eiji Oki,Takayuki Yoshino","doi":"10.1016/j.ccell.2026.08.001","DOIUrl":"https://doi.org/10.1016/j.ccell.2026.08.001","url":null,"abstract":"Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenges conventional randomized designs. We propose an MRD Registry as an external control cohort that integrates quantitative ctDNA data with outcomes to validate ctDNA dynamics as response indicators—facilitating efficient MRD-based trial design and accelerating novel therapy development.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"24 1","pages":""},"PeriodicalIF":50.3,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148957859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
